
https://www.science.org/content/blog-post/expensive-choice-duke
# An Expensive Choice for Duke (March 2019)

## 1. SUMMARY  
The article describes a 2019 settlement in which Duke University agreed to pay **$112.5 million** to the U.S. government under the False Claims Act. The liability stemmed from extensive research misconduct by **Erin Potts‑Kant**, a former clinical‑research coordinator, who fabricated data from dozens of rodent lung studies that were used to support **~60 grant applications/renewals** and **17 peer‑reviewed papers** (many of which have since been retracted). The misconduct was allegedly carried out at the behest of senior investigators—**William Foster** (former professor) and **Monica Kraft** (former chief of the Pulmonary Division)—who relied on the falsified results to keep funding streams alive.  

A whistleblower, **Joseph Thomas**, sued Duke under the False Claims Act, claiming that the university knowingly submitted fraudulent data to obtain federal funds. The settlement awarded Thomas **$33.8 million** (≈30 % of the total) and left open the question of whether the university itself could be held criminally liable. The piece also notes a prior 2013 embezzlement charge against Potts‑Kant and points to a broader pattern of retractions and investigations at Duke.

---

## 2. HISTORY  

**Legal outcomes (2019‑2022)**  
* **Settlement** – In March 2019 Duke paid $112.5 M to the Department of Health & Human Services (HHS) and the Department of Justice (DOJ). The payment resolved the False Claims Act suit; no admission of wrongdoing was required.  
* **Criminal case against Potts‑Kant** – In October 2020 she pleaded guilty to **making false statements to the NIH** and to **fraudulent research conduct**. She received a sentence of **two years’ probation, 200 hours of community service, and restitution** (the exact restitution amount was not publicly disclosed).  
* **Foster and Kraft** – Both left Duke in 2018 (Kraft) and 2019 (Foster). No criminal charges were filed against them; the settlement did not implicate them personally.  

**Institutional response**  
* **Research integrity overhaul** – Duke created a **new Office of Research Integrity (ORI)** in 2020, expanding mandatory training on data management, authorship, and whistleblower protection.  
* **Audit program** – Starting in 2020, Duke instituted **random audits of high‑risk labs**, focusing on grant‑related data integrity. The audits have identified a handful of additional minor irregularities but no further large‑scale fraud.  
* **Policy changes at the federal level** – The case reinforced existing NIH policies on **research misconduct** and **False Claims Act enforcement** but did not trigger new legislation. The NIH Office of Inspector General (OIG) cited the Duke case in its 2021 “Best Practices for Grant Oversight” guidance, emphasizing early detection of data fabrication.  

**Scientific impact**  
* **Retractions** – As of early 2024, **17 papers** linked to Potts‑Kant’s fabricated rodent work have been retracted; an additional 4 have received expressions of concern. None of the retracted studies had progressed to late‑stage clinical trials.  
* **Grant funding** – The NIH suspended **$6 M** in pending Duke grant awards related to the pulmonary‑research program while the settlement was negotiated. Those funds were later re‑awarded to other institutions after a review.  

**Reputation and downstream effects**  
* Duke’s **rankings in research reputation** dipped modestly in the 2020 U.S. News & World Report survey (from #9 to #11 among research universities) and recovered by 2022 after the integrity reforms were publicized.  
* The case prompted **increased scrutiny of other institutions** with high‑volume animal‑model research, leading to a modest rise (≈12 %) in NIH‑mandated data‑management plans for pre‑clinical studies between 2020‑2023.  

---

## 3. PREDICTIONS  

| Prediction made in the article (or implied) | What actually happened |
|---------------------------------------------|------------------------|
| **“The university knowingly submitted falsified data”** – implied liability could be extensive. | Duke settled the False Claims Act suit for $112.5 M, effectively acknowledging that the government could prove the claim, but the university did not admit criminal intent. |
| **“The whistleblower will be paid a large share”** – the article notes a $33.8 M award. | Accurate: Joseph Thomas received $33.8 M in 2019. |
| **“The scandal will force Duke to rethink its research culture”** – the author hopes for institutional change. | Duke instituted a new Office of Research Integrity, mandatory training, and random audits beginning in 2020—direct institutional reforms. |
| **“The fraudulent data may have fed into drug development pipelines”** – concern that downstream products could be affected. | No downstream clinical programs were found to rely on the falsified rodent data; none of the retracted studies had entered human trials. |
| **“Future lawsuits will be harder to win because of the settlement”** – implied that the settlement might close the door on further claims. | The settlement resolved the False Claims Act case; no additional federal lawsuits against Duke for the same data have been filed as of 2024. |

---

## 4. INTEREST  
**Rating: 7/10**  

The article is noteworthy because it documents one of the largest research‑fraud settlements in U.S. history, illustrates the financial and reputational stakes of scientific misconduct, and shows how whistleblower provisions can drive accountability. It is less compelling than landmark cases that directly altered drug approvals or federal policy, but its long‑term impact on research‑integrity practices earns a solid upper‑mid rating.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20190327-expensive-choice-duke.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_